General Information Document Type: Presolicitation Synopsis Number: 75N98026Q00532 Posted Date: June 5, 2026 Original Response Date: June 15, 2026 Current Response Date: June 15, 2026 Set Aside: N/A NAICS Code: 513120 Contracting Office Address National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817 Description INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: 3821 Woodley RD NW Washington, District Of Columbia 20016-3701, United States NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 513120 with a Size Standard $1000. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-99-1, July 16, 2018. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: SUBSCRIPTION TO THE CANCER LETTER Background Information: The National Institutes of Health, National Cancer Institute (NCI) is the nation's leading federal agency for cancer research. This request is for a subscription to "The Cancer Letter", in an effort to provide 3,000-4,000 NCI staff swift and unencumbered access to the newsletter. The Federal Acquisition Regulation (FAR) provision FAR 52.211-6, Brand Name or Equal (AUG 1999) is applicable to this requirement. The importance of establishing enterprise-wide access to this subscription is to ensure that discoveries in NCI-supported research and clinical trials as well as information on other developments of cancer therapies, cancer research funding, health care finance, legislation and policy that impacts the work and mission of NCI. Over the past 4 decades, The Cancer Letter has provided information about cancer research, on a weekly basis, to an audience consisting of academic cancer centers, biotechnology and pharmaceutical companies, governmental agencies and other news media. The resulting journalistic outcome from this com…